Articles with public access mandates - Susan BlaneyLearn more
Not available anywhere: 1
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group
PA Thompson, M Gupta, GL Rosner, A Yu, J Barrett, L Bomgaars, ...
Cancer chemotherapy and pharmacology 62, 1027-1037, 2008
Mandates: US National Institutes of Health
Available somewhere: 90
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
YP Mossé, MS Lim, SD Voss, K Wilner, K Ruffner, J Laliberte, D Rolland, ...
The lancet oncology 14 (6), 472-480, 2013
Mandates: US National Institutes of Health
Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group Study
YP Mossé, SD Voss, MS Lim, D Rolland, CG Minard, E Fox, P Adamson, ...
Journal of Clinical Oncology 35 (28), 3215-3221, 2017
Mandates: US National Institutes of Health
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study
EA Raetz, MS Cairo, MJ Borowitz, SM Blaney, MD Krailo, TA Leil, JM Reid, ...
Journal of Clinical Oncology 26 (22), 3756-3762, 2008
Mandates: US National Institutes of Health
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group
S Malempati, B Weigel, AM Ingle, CH Ahern, JM Carroll, CT Roberts, ...
Journal of Clinical Oncology 30 (3), 256-262, 2012
Mandates: US National Institutes of Health
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report
M Fouladi, JR Park, CF Stewart, RJ Gilbertson, P Schaiquevich, J Sun, ...
Journal of Clinical Oncology 28 (22), 3623-3629, 2010
Mandates: US National Institutes of Health
Nanoshell-mediated photothermal therapy improves survival in a murine glioma model
ES Day, PA Thompson, L Zhang, NA Lewinski, N Ahmed, RA Drezek, ...
Journal of neuro-oncology 104, 55-63, 2011
Mandates: US National Institutes of Health
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I …
JL Glade Bender, A Lee, JM Reid, S Baruchel, T Roberts, SD Voss, B Wu, ...
Journal of clinical oncology 31 (24), 3034-3043, 2013
Mandates: US National Institutes of Health
Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group …
JP Lagmay, MD Krailo, H Dang, AR Kim, DS Hawkins, O Beaty III, ...
Journal of Clinical Oncology 34 (25), 3031-3038, 2016
Mandates: US National Institutes of Health
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group
B Weigel, S Malempati, JM Reid, SD Voss, SY Cho, HX Chen, M Krailo, ...
Pediatric blood & cancer 61 (3), 452-456, 2014
Mandates: US National Institutes of Health
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I …
YP Mossé, E Lipsitz, E Fox, DT Teachey, JM Maris, B Weigel, ...
Clinical cancer research 18 (21), 6058-6064, 2012
Mandates: US National Institutes of Health
Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium
R Aplenc, SM Blaney, LC Strauss, FM Balis, S Shusterman, AM Ingle, ...
Journal of clinical oncology 29 (7), 839-844, 2011
Mandates: US National Institutes of Health
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 …
ML Loh, SK Tasian, KR Rabin, P Brown, D Magoon, JM Reid, X Chen, ...
Pediatric blood & cancer 62 (10), 1717-1724, 2015
Mandates: US National Institutes of Health
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
RI Jakacki, M Hamilton, RJ Gilbertson, SM Blaney, J Tersak, MD Krailo, ...
Journal of Clinical Oncology 26 (30), 4921-4927, 2008
Mandates: US National Institutes of Health
Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's …
LM Wagner, M Fouladi, A Ahmed, MD Krailo, B Weigel, SG DuBois, ...
Pediatric blood & cancer 62 (3), 440-444, 2015
Mandates: US National Institutes of Health
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study
SG DuBois, S Shusterman, AM Ingle, CH Ahern, JM Reid, B Wu, ...
Clinical Cancer Research 17 (15), 5113-5122, 2011
Mandates: US National Institutes of Health
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's …
R Bagatell, R Norris, AM Ingle, C Ahern, S Voss, E Fox, AR Little, ...
Pediatric blood & cancer 61 (5), 833-839, 2014
Mandates: US National Institutes of Health
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report
BC Widemann, AR Kim, E Fox, S Baruchel, PC Adamson, AM Ingle, ...
Clinical Cancer Research 18 (21), 6011-6022, 2012
Mandates: US National Institutes of Health
Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report
JM Su, XN Li, P Thompson, CN Ou, AM Ingle, H Russell, CC Lau, ...
Clinical cancer research 17 (3), 589-597, 2011
Mandates: US National Institutes of Health
A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children’s Oncology Group
S Baruchel, A Pappo, M Krailo, KS Baker, B Wu, D Villaluna, M Lee-Scott, ...
European Journal of Cancer 48 (4), 579-585, 2012
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program